Further, autoinjectors have improved patient compliance and adherence as they enable patients to self-inject their medications easily and reduce anxiety associated with the traditional injection methods. Further, these devices are user-friendly and integrated with intuitive features (including visual and auditory cues) to ensure proper use and minimize the risk of dosing errors; this in turn gives the patients greater control over their health and well-being.

Key Report Takeaways

Presently, around 150 autoinjectors are commercially available / being manufactured by close to 50 companies, across the world; notably, majority of the autoinjector manufacturers were established between 1986 and 2015

Currently, majority of the autoinjectors available in the market are suitable for subcutaneous administration of drugs; over 35% of the autoinjectors are intended to deliver peptides

Autoinjector manufacturers are continuously integrating advanced features in their products in order to achieve an edge over their competitors

Owing to the growing demand for autoinjectors, a number of players have entered the market to develop innovative technologies and establish a strong footprint in the autoinjectors industry

Majority of the deals inked in the autoinjector domain were product development agreements; further, most of the intercontinental deals have been signed by players based in Europe and North America

Since 2019, over 1,100 patents related to autoinjectors have been filed by / granted to various stakeholders; of these, majority are patent applications

More than 150 auto-injector combination products are commercialized across the world; further, over 40% of the developers (of these products) are based in North America

Over 70 autoinjector combination products are currently under development (primarily in the clinical stages); most of these are being developed for the treatment of chronic conditions

The autoinjectors market is anticipated to grow at a CAGR of 6.2%, till 2035; North America is anticipated to drive the autoinjector market in coming years

Competitive Landscape of Autoinjectors Market

The market features around 150 autoinjectors. Close to 65% of the autoinjectors are designed for single use and can be discarded later. Further, over 75% of the autoinjectors are compatible with syringes (either prefilled or fillable) for storing drugs. In terms of autoinjector manufacturers, the overall landscape seems to be well-fragmented, featuring the presence of both established companies as well as emerging start-ups. Majority of the firms are small players, followed by mid-sized firms and very large firms.

Autoinjectors Market Regional Outlook

Based on the key geographical regions, the autoinjector market can be segmented into six major regions, including North America, Europe, Asia Pacific, Middle East and North Africa and Latin America. Notably, North America is anticipated to dominate the autoinjectors market in 2024 and this trend is likely to remain unchanged during the forecast period.

Further, Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the market in the region is driven by the increasing prevalence of chronic diseases, along with a growing need for emergency care in home care settings.

Key Players

Examples of key companies engaged in autoinjectors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, Antares Pharma, ChemProtect.SK, Elcam Medical, Eli Lilly and Company, Jiangsu Delfu Medical Device, Kindeva Drug Delivery, Merck, Novartis, Novo Nordisk, Oval Medical Technologies, Owen Mumford, PreciHealth, Recipharm, Sanofi, SHL Medical, Teva Pharmaceuticals, Union Medico, Ypsomed.

It is interesting to note that in January 2024, Ypsomed participated in Pharmapack Conference, held in Paris, France to showcase its expertise in self-injection devices, including the YpsoMate 5.5 large volume autoinjector.

Market Segments

Based on research, Roots Analysis has segmented the autoinjectors market into Usability, Route of Administration, Type of Molecule Delivered, Actuation mechanism, Volume of Container, End-user, Target Indication and Key Geographical Regions.

by Usability

Disposable Autoinjectors

Reusable Auto injectors

by Route of Administration

Subcutaneous

Intramuscular

Intravenous

by Type of Molecule Delivered

Proteins

Antibodies

Small Molecules

Peptides

Others

by Type of Actuation Mechanism

Manual

Automatic

by Volume of Container

Less than 1 mL

1-2 mL

More than 2 mL

by End User

Home Care Settings

Hospitals and Clinics

Ambulatory Surgical Centers

by Therapeutic Indication

Rheumatoid Arthritis

Multiple Sclerosis

Diabetes

Weight Loss

Anaphylaxis

Migraine

Other Indications

by Key Geographical Regions

North America

Europe

Asia-Pacific

Middle East and North Africa

Latin America

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com